摘要
前列腺癌是影响男性健康的常见病之一,早期诊断和治疗对改善患者预后有重要作用。目前,前列腺特异抗原(PSA)作为前列腺癌筛查中应用最广泛的血清学指标,在提高早期诊断率和降低死亡率方面起着非常重要的作用,但PSA灵敏度较高,使很多非前列腺癌患者接受了不必要的穿刺活组织检查或过度治疗。与PSA相比,新血清学指标前列腺健康指数(PHI)具有更高的诊疗价值。PHI能减少不必要的穿刺活组织检查,还可对根治性前列腺切除术(RP)患者的预后进行评估,提高患者主动监测的积极性,为临床医师下一步治疗方案的制定提供重要信息。本文就PHI对前列腺癌的诊断价值、PHI与肿瘤体积的关系、PHI与其他影像学联合诊断及对行RP患者的预后评估价值等方面进行综述。
Prostate cancer is one of the common diseases affecting men′s health.Early diagnosis and treatment can make a difference in greatly improving the prognosis of patients.At present,prostate specific antigen(PSA),the most widely used serum indicator in prostate cancer screening,plays an important role in improving the early diagnosis rate and reducing mortality,but the high sensitivity of PSA makes many non-prostate cancer patients receive unnecessary puncture biopsies or overtreatment.Compared with PSA,prostate health index(PHI)has higher diagnostic value.PHI can reduce unnecessary puncture biopsies,and evaluate the prognosis of patients after prostatectomy(RP),which can motivate patients to actively monitor and provide important information for clinicians to formulate the following treatment plan.This article reviews the diagnostic value of PHI in prostate cancer,the relationship with tumor volume,the combined diagnosis with other imaging tests,and the prognostic value for patients undergoing RP.
作者
徐秀
石怡珍
Xu Xiu;Shi Yizhen(Department of Nuclear Medicine,the Second Affiliated Hospital of Soochow University,Suzhou 215004,China)
出处
《中华核医学与分子影像杂志》
CAS
CSCD
北大核心
2022年第1期48-51,共4页
Chinese Journal of Nuclear Medicine and Molecular Imaging
